Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI

Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.

View of Darolutamide (Nubeqa) Canadian Journal of Health

ARASENS: Darolutamide Plus ADT and Docetaxel May Become New

Prostate Cancer Treatment (PDQ®) - NCI

View of Darolutamide (Nubeqa) Canadian Journal of Health

Darolutamide and Survival in Metastatic, Hormone-Sensitive

Focus on Transitional Disease: A Critical Interval to Delay

Frontiers YIV-818-A: a novel therapeutic agent in prostate

Darolutamide and Survival in Metastatic, Hormone-Sensitive

Androgen receptor pathway inhibitors, prostate cancer, and older

Darolutamide is a potent androgen receptor antagonist with strong

Targeting myeloid chemotaxis to reverse prostate cancer therapy